Curis is betting heavily on one cancer drug, and upcoming trial results and possible faster approvals could open the door to treating several blood cancers. The flip side is that without any approved products yet, a single setback—or tougher competition and funding needs—could quickly change the outlook.Read more
Curis is betting its lead cancer drug, emavusertib, could reach patients faster than many expect and quickly become a go-to option in several blood cancers. The upside hinges on smooth regulator decisions and standing out in a crowded field, but thin funding and tough competition could derail the rollout.Read more
Curis is betting heavily on one experimental cancer drug, and that makes the company unusually exposed to trial results, regulator decisions, and fast-moving rivals. If approvals take longer than expected or competitors move quicker, the business may need to raise more money and could struggle to turn promising science into a real product.Read more
No trending discussion available.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
